Journal article
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer
Nick Pavlakis, Caroline Cooper, Thomas John, Steven Kao, Sonja Klebe, Chee Khoon Lee, Trishe Leong, Michael Millward, Ken O'Byrne, Prudence A Russell, Benjamin Solomon, Wendy A Cooper, Stephen Fox
Pathology | ELSEVIER | Published : 2019
Abstract
Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58-83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2-39.1 months) and median overall survival (..
View full abstract
Grants
Funding Acknowledgements
Editorial support for the development of this article was funded by Pfizer Ltd Australia, the manufacturer of crizotinib. NP has participated as an advisory board member and received honoraria from Bristol-Myers Squibb, Merck-KgA, Boehringer Ingelheim, Astra Zeneca, Roche, Bayer, Novartis, Merck-Serono, Pfizer, Takeda and Ipsen. NP has also received research funding to his institution from Bayer and Pfizer, and travel funding from Boehringer Ingelheim, Bristol-Myers Squibb and Roche. CC has participated as an advisory board member for Merck, Sharp & Dohme and has received travel and accommodation expenses from Merck, Sharp & Dohme and Pfizer. TJ has participated as an advisory board member for BMS, AstraZeneca, Ignyta, Takeda, Roche, Pfizer and Novartis. SKao has received funding from Pfizer, AstraZeneca, Roche, Bristol-Myers Squibb, MSD Oncology and Boehringer Ingelheim. SK has participated as an advisory board member for Pfizer, Roche and MSD Oncology. CKL has participated as an advisory board member for AstraZeneca, Novartis, Pfizer, Roche and Takeda. TL has no disclosures in relation to the current work. MM has participated as an advisory board member for Astra-Zeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer and Roche. KO'B has received funding from Merck, Sharp & Dohme, Bristol-Myers Squibb, Roche, Teva, Boehringer Ingelheim, AstraZeneca, Pfizer/EMD Serono, Novartis, Janssen and Mundipharma. PAR has no disclosures in relation to the current work. BS has participated as an advisory board member for Pfizer, Roche/Genentech, Novartis, Bristol Myers Squibb, Merck, Loxo Oncology and Gritstone Oncology. WC has participated as an advisory board member for Pfizer, MSD and Bristol-Myers Squibb. SF has participated as an advisory board member for Pfizer, AZ, BMS, MSD, Novartis and Roche.